NextBio

Help
Description: Vapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.
Drug Type: Small Molecule; Approved; Investigational
Pharmacology: Vapreotide is a somatostatin analog with a higher metabolic stability than the parent hormone. Vapreotide reduces splanchnic blood flow; inhibits growth hormone release, and inhibits the release of peptides and vasoactive compounds from neuroendocrine tumors.
Mechanism of Action: The exact mechanism of action is unknown, although one study has provided in vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect in the analgesic effects of vapreotide (PMID: 7556407).
Indication: For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.
Half Life: 30 minutes
View Complete Description



Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving Vapreotide.

View All Author iconAuthors
  • K Besseghir
  • J Lavarenne
  • R Deghenghi
  • M Papotti
  • E Ghigo
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • Mayo Clinic
  • Debiovision
View All Affiliations icon Organizations
  • Université d'Angers
  • University of Geneva
  • Faculté de Médecine
  • University of Colorado at Denver
  • Mayo Clinic

Clinical Trials | 2 trials

Help for Clinical Trials View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “Vapreotide”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

NextBio Groups

  • No NextBio groups were found for “Vapreotide”.
    Be the first to start a group and share your interests with others within the NextBio community.

© 2010 NextBio